Podcasts about tirzepatide

EP. 207: A new study on tirzepatide just dropped, and some obesity experts claim it confirms that the drug works only by reducing calories. After reading the full paper myself, I've got a different take. In this episode, I unpack what the study actually shows—like how tirzepatide increases fat oxidation without impacting metabolic adaptation—and why the “calories in, calories out” story doesn't tell the whole truth. There's more going on here, and you deserve the full picture. Topics Covered: Does tirzepatide help with metabolic health beyond calorie restriction leading to weight loss? How does it affect metabolic adaptation in people with obesity? Can it boost fat oxidation? Is the “calories in, calories out” model outdated for GLP-1s? What does this mean for long-term metabolic health? Sponsored By: Qualia | Go to qualialife.com/DRTYNA for up to 50% off your purchase and use code DRTYNA for an additional 15% Sundays | As a Listener of The Dr Tyna Show, you can Get 40% off your first order of Sundays. Go to sundaysfordogs.com/DRTYNA and use code DRTYNA at checkout. Liver Love | Go to https://store.drtyna.com/products/liverlove Use code DRTYNASHOW at checkout to save. LMNT | Get your free Sample Pack with any LMNT purchase at drinkLMNT.com/drtyna BIOptimizers | For an exclusive offer on MassZymes go to Bioptimizers.com/DRTYNA and use promo code DRTYNA On This Episode We Cover:  00:00:00 – Introduction  00:02:44 – Obesity study on GLP1s and weight loss 00:04:21 – Calories in vs. calories out 00:05:44 – Resting metabolic rate 00:09:25 – Metabolic adaptation during dieting 00:12:11 – Tirzepatide dosing in clinical studies 00:15:49 – Maintaining weight loss 00:18:15 – GLP1s &  increased fat oxidation 00:19:14 – GLP1 microdosing myths 00:26:06 – Metabolic rate drops vs. metabolic improvements 00:29:51 – Lessons from the Biggest Loser study 00:34:20 – Study Comparation 00:35:25 – Weight loss, inflammation, and aging 00:36:35 – Health autonomy  00:40:23 – Caloric restriction and the CALERIE study Studies Mentioned:  Tirzepatide Did Not Impact Metabolic Adaptation In People With Obesity, But Increased Fat Oxidation Persistent Metabolic Adaptation 6 Years After The Biggest Loser Competition Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy (CALERIE) Show Links GLP-1s Done Right University Dr. Tyna's Strength Corner Metabolic Revamp Toolkit + Masterclass Further Listening:  GLP1s Uncovered (Free Class) EP. 202 | The Fight for Affordable GLP1s & the Truth About Big Pharma | Dave Knapp Disclaimer: Information provided in this podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. Information provided in this blog/podcast and the use of any products or services related to this podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Eli Lilly will start a lcinical trial for tirzepatide for people with type 1 diabetes, more details on Dexcom's 15 day G7 sensor, Ozepmic pill form tested, type 5 diabetes identified and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Our top story this week.. Eli Lilly takes the first steps toward getting tirzepatide approved for people with type 1 diabetes. Tirzepatide is sold under the brand names Mounjaro for type 2 and Zepbound for obesity. The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or are overweight. Participation in the study will last about 49 weeks. Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight This is a big deal because, even though many people with type 1 are able to get a prescription for tirzepatide, it's not approved for T1D and so insurers won't usually cover it.   https://clinicaltrials.gov/study/NCT06914895 XX The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there's little information on the drugs' safety and effectiveness for the condition. The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can't make enough of their own. Drugmakers feared that using the GLP-1 medications with insulin might raise the chance of dangerously low blood sugar events, or hypoglycemia, and were unwilling to take the risk of studying them in people with type 1.   For the study, which was published last month in the journal Diabetes, Obesity, and Metabolism, researchers at Johns Hopkins University reviewed the medical records of more than 200,000 people with type 1 diabetes from 2008 to 2023. They grouped the data in three-year periods, starting with October 2008 to September 2011 and ending with October 2020 to September 2023. GLP-1 medication use spiked, as well. Among adults with the highest category of obesity, about 4% used GLP-1 medications in 2008, and 33% did by 2023 – an 800% increase. But these are anecdotal reports and may not reflect instances in which people have side effects or complications like low blood sugar, which can be life-threatening. But Shin says what's really needed is information from randomized, double-blinded studies, in which participants are followed forward in time and given either a drug or a placebo. https://www.cnn.com/2025/04/09/health/glp-1-type-1-diabetes-study/index.html   XX Later this month the FDA will conduct a final meeting regarding a new, investigational compound (sotagliflozin) soda-GLIFF-a-zin that has been shown to Improve QoL and Reduce Long-term Complications for people with type 1 diabetes (T1D). The patient advocacy group Taking Control of Your Diabetes (TCOYD.org) is working to inform the T1D community about sotagliflozin - and to encourage people to sign a Change.org petition directed towards FDA.  Last fall, the FDA declined to approve sotagliflozin due to concerns about a potential increased risk of diabetic ketoacidosis (DKA), despite this being a condition that people with T1D on insulin face and manage daily. While TCOYD respects FDA's caution, the group stands by T1D patients and their physicians who, as a team, balance risks and benefits every day. https://tcoyd.org/petition/ XX Dexcom receives FDA approval for it's G7 with 15 day wear. We have an interview with Chief Operating Officer Jake Leach coming up on Tuesday – we talk about the planned roll out of this sensor, what else has changed, and the fine print in the press release – it says    “A study was conducted to assess the sensor life where 73.9% of sensors lasted the full 15 days. When using the product per package labeling, approximately 26% of sensors may not last for the full 15 days.   https://investors.dexcom.com/news/news-details/2025/Dexcom-G7-15-Day-Receives-FDA-Clearance-the-Longest-Lasting-Wearable-and-Most-Accurate-CGM-System/default.aspx?utm_source=www.diabetech.info&utm_medium=referral&utm_campaign=dexcom-g7-15-day-sensor-gets-fda-cleared-but-will-it-actually-last-that-long   XX Glucotrack is joining something called  FORGETDIABETES bionic pancreas initiative, - this is an European Union project that aims to develop a long-term automated insulin delivery system for type 1 diabetes patients. Glucotrack's Continuous Blood Glucose Monitor (CBGM) will be integrated into the system to provide real-time glucose readings. The initiative's goal is to create a bionic invisible pancreas that eliminates the need for therapeutic actions and reduces psychological burden.   The architecture of BIP encompasses a ground-breaking, lifelong lasting implanted ip glucose nanosensor; a radically novel ip hormone delivery pump, with unique non-invasive hormone refill with a magnetic docking pill and non-invasive wireless battery recharge; an intelligent closed-loop hormone dosing algorithm, optimized for ip sensing and delivery, individualized, adaptive and equipped with advanced self-diagnostic algorithms.     Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of pain and awkward daily measurement and treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. key feature of BIP is to be fully-implantable and life-long lasting thanks to novel biocompatible and immune-optimized coatings guaranteeing long-term safety and stability https://www.stocktitan.net/news/GCTK/glucotrack-to-participate-in-forgetdiabetes-a-prominent-european-cjjldjb0dq7h.html XX A newly recognised form of diabetes, called Type 5, was announced this week at the World Congress of Diabetes 2025. A global task force will investigate this less-understood condition, which differs from Type 1 and Type 2 diabetes. Type 5 diabetes affects people who are underweight, lack a family history of diabetes and do not show the typical symptoms of Type 1 or Type 2 diabetes. The condition was first observed in the 1960s and referred to as J-type diabetes, after being detected in Jamaica. It was classified by the World Health Organisation in 1985, but removed in 1998 due to lack of physiological evidence. At the time, experts believed it to be a misdiagnosed case of Type 1 or 2 diabetes. New research has since confirmed that Type 5 is different. https://economictimes.indiatimes.com/news/new-updates/a-new-type-of-diabetes-has-been-found-by-scientists-and-it-doesnt-show-the-typical-symptoms-of-type-1-or-type-2/articleshow/120276658.cms?from=mdr   XX Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. A new clinical trial, co-led by endocrinologist and diabetes specialist John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine, has demonstrated that the oral form of semaglutide significantly lowers the risk of cardiovascular events in individuals with type 2 diabetes, atherosclerotic cardiovascular disease, and/or chronic kidney disease. Results from the rather large, international trial were published in the New England Journal of Medicine and presented at the American College of Cardiology's Annual Scientific Session & Expo in Chicago, Illinois.     The effect of oral semaglutide on cardiovascular outcomes was consistent with other clinical trials involving injectable semaglutide, but more trials are needed to determine if one method may be more effective than the other at reducing major cardiovascular events. https://scitechdaily.com/new-pill-form-of-semaglutide-shows-major-benefits-for-people-with-diabetes/ XX April 14 (UPI) -- The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to treat Type 2 diabetes, have been found in the United States. Novo Nordisk, the Danish-headquartered manufacturer, informed the FDA on April 3 that counterfeit 1-milligram injections of semaglutide were being distributed outside its authorized supply chain. The FDA and Novo Nordisk are testing the fake products to identify whether they're safe. Patients are asked to obtain Ozempic with a valid prescription through state-licensed pharmacies and check the product for any signs of counterfeiting. People in possession of the fake product are urged to call Novo Nordisk customer care at 800-727-6500 Monday through Friday from 8:30 a.m. to 6 p.m. EDT and report it to the FDA's criminal activity division's website. Side effects can be reported to FDA's MedWatch Safety Information and Adverse Event Reporting Program (800-FDA-1088 or www.fda.gov/medwatch) as well as to Novo Nordisk, at 800-727-6500. https://www.upi.com/Health_News/2025/04/14/FDA-fake-Ozempic-drugs-Novo-Nordisk/6841744666854/ XX Can a digital lifestyle modification program reduce diabetes risk? A new study shows that the lifestyle intervention significantly reduced 10-year diabetes risk among prediabetics by nearly 46% and increased the diabetes remission rate, highlighting the importance of lifestyle changes. However, the study was not a randomized trial, and participation in the lifestyle intervention was voluntary, which may introduce selection bias. The study evaluated 133,764 adults, categorizing them as diabetic (7.5%), prediabetic (36.2%), and healthy (56.3%), based on fasting glucose and HbA1c levels. https://www.news-medical.net/news/20250414/Digital-lifestyle-program-cuts-diabetes-risk-by-4625-in-prediabetics-study-of-130k2b-adults-reveals.aspx XX Chrissy Teigan is speaking out about her son's type 1 diagnosis – teaming up with Sanofi to encourage people to screen early for Type 1 diabetes.   Teigen got a crash course in the risks of undiagnosed Type 1 diabetes when her 6-year-old son, Miles, was hospitalized with complications of the autoimmune disease last year. The family knew nothing about Type 1 diabetes when Miles was diagnosed during an unexpected medical emergency, Teigen said in a Tuesday announcement. “We were confused and scared when Miles was first diagnosed,” she said in a statement. “There is no doubt in my mind that knowing in advance would have made a positive impact for Miles, me, and our entire family. I want everyone to hear me when I say: stay proactive and talk to your doctor about getting yourself or your loved ones screened for type 1 diabetes today!”   Teigen shared her family's story in a two-minute video on ScreenForType1.com, a Sanofi website that discusses how to get screened for the condition. Miles' diagnosis made Teigen feel like she “went from a mom to a doctor overnight,” she said. That experience is why Teigen said she is “begging you: Do this one thing, and screen yourself and your family for Type 1 diabetes.” https://www.fiercepharma.com/marketing/sanofi-signs-chrissy-teigen-diabetes-screening-campaign XX Dr. Richard Bernstein – best known for his advocacy around low carb diets for people with diabetes – died this week at the age of 90. Born in 1934 in Brooklyn, New York, he was diagnosed with type 1 at age 12. In the 1970s he adapted a blood glucose monitor for home use and helped pioneer home glucose monitoring. He published multiple books on Diabetes including the #1 selling Diabetes book on Amazon.Com “Dr. Bernstein's Diabetes Solution: A Complete Guide to Achieving Normal Blood Sugars” and “Diabetes Type II: Living a Long, Healthy Life Through Blood Sugar Normalization”.  He practiced and saw patients right up until his death.

**Dr. Lisa Faast shares important news about tirzepatide compounding. After a shortage, the FDA reversed its decision and now allows pharmacies to compound and sell tirzepatide again. She covers the latest updates, suppliers like Lone Star Pharmaceuticals, BPI Labs, and PQ Pharma, and tips on staying compliant with state boards. Stay informed by joining the APC Alliance.** **Show Notes:** 1. **FDA Reversal on Tirzepatide Compounding** [0:00] 2. **Clarification from the FDA ** [2:51] 3. **Availability and Cost of Tirzepatide ** [5:09] 4. **State Regulations and Documentation** [6:31] 5. **Final Thoughts and Resources** [7:02] **Websites Mentioned: https://lonestarpharmaceuticals.com/ https://bpilabs.com/ https://www.pqpharmacy.com/s/ https://diversifyrx.com/weekly-awesomeness-newsletter/ https://www.drlisafaast.com/ ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be Apart of the Pharmacy Podcast Network**

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes. Overall, their findings show a significant uptick in tirzepatide dispensations, alongside other glucose- and weight-lowering medications, including semaglutide.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog The newest miracle drug for weight loss is changing the lives of thousands of people who have battled obesity for extended periods of time….These GLP-1 medications are also treating or preventing the diseases that go with long term obesity: Diabetes, Heart Disease, Joint replacements, Arthritis, Sleep Apnea, and Alzheimer's Disease. Researchers are finding more indications every day for patients to take these weight loss medications. But like anything else there is no perfect answer to any problem.  Among the few side effects of this drug, the most frequent side effect is reflux, also called acid indigestion, or GERD (gastroesophageal reflux disease).  Often my patients don't even know what their diagnosis is, they just tell me about their symptoms. The symptoms of GERD include: Asthma symptoms A bad taste in the mouth Difficulty swallowing Dry, hacking, cough Chest pain after meals These symptoms are worse after a big meal, at bedtime, after spicy food, or dose related.  Most of my patients don't want to discontinue the GLP-1 inhibitors because they are finally losing weight!  We manage the GLP-1 side effect of GERD by decreasing dose of the medication and slowly increase the dose back to an effective level. We also offer lifestyle and dietary treatments before we offer prescription medication. Therefore, if reflux is not constant, and is not causing any lasting damage to the patient's esophagus, we can treat it with lifestyle changes and over the counter medication, to lower the stomach acid that is refluxing into the esophagus. The lifestyle changes patients can employ on their own are described below. Lifestyle changes needed to avoid or treat Gastric Reflux caused by GLP-1 agonists. What can you do to prevent and treat this side effect: Eat smaller meals: Large meals expand your stomach and put pressure on your lower esophageal sphincter (LES). Don't go to bed less than 2 hours after eating Avoid trigger foods see below Sleep on your left side Elevate the head of your bed Avoid tight clothing: Chew your food well– chew each bite for 20 seconds. Quit smoking: Smoking weakens your LES and makes your stomach more acidic. Stop drinking alcohol Chew (non-mint) sugar-free–gum  In addition to changing your active lifestyle, changing your diet is necessary as well. There are trigger foods to avoid minimizing your reflux symptoms.  tomato sauce and other tomato-based products high fat foods, such as fast food and greasy foods fried foods citrus fruit juices soda-diet and regular Caffeine Garlic onions mint of any kind milk based products My patients ask me, “So what can I eat?” …I admit I did take away some of the most exciting foods, however my patients ask me what they can eat so the list of foods that help avoid and treat GERD are listed below. High-fiber foods: vegetables, fruit, and whole grain bread. Alkaline foods. Foods fall somewhere along the pH scale (turns litmus paper blue). Drink alkalinized water (PH > 8) Ginger—fresh sushi Ginger from Asian food stores. Apple cider vinegar on salads and a Tablespoon in water every morning Lemon water—just squeeze a slice of lemon in your water. Coconut water Honey. Lean Protein including meat Low-Fat and Nonfat Dairy Products. Non-Citrus Fruits like apples, pears, bananas, and melons Vegetables like broccoli, Carrots, Corn, Cucumbers, Green Beans, Green peppers, Potatoes and Sweet potatoes   For my patients who take herbal and other supplements, the following is a list of the supplements that may decrease your symptoms of GERD. Chamomile Tea Licorice Marshmallow Slippery Elm Tablets Probiotics-Mega Brand Prebiotics-Mega Digestive Enzymes Aloe Vera Juice Baking Soda Magnesium glycinate What happens when you have made all the lifestyle changes you can and have lowered your GLP-1 dose or changed to a different type of GLP-1 Agonist, and you still have GERD? As a physician I prescribe medications to help my patients treat their GERD, however most of the medications have been placed over the counter so I can recommend them to my patients, and they can buy the medication without a script. The class of medication that treats GERD include Antacids, H2 Blocker, and Proton Pump Inhibitor.  Antacids neutralize stomach acid, but they typically only work for short periods. They are generally made of calcium. This type of medication is best used prn for symptom relief.  Side effects of antacids may include constipation and diarrhea. The second option for treatment of GERD is an H2 blocker. These drugs reduce the amount of acid the stomach releases. Eg. Pepcid, Tagamet, Gaviscon. Proton pump inhibitors (PPIs): These drugs are available by prescription from a healthcare provider, and now some doses are over the counter. PPIs help reduce the amount of acid the stomach makes.  They should be used for a two-week period only for severe attacks and then you should change to an H2 blocker or antacid. WHY stop a PPI after 2 weeks?   Omeprazole is an example of a PPI.  Theses medication kill the good bacteria in your intestines, change your breath and can affect how you absorb your nutrients. If you must take them chronically to treat and prevent the progression of damage to the esophagus. What if I did everything and GERD is still a problem: If your condition is severe, your doctor may recommend a consultation with a GI doctor for an endoscope or other diagnostic procedure.  In addition, you may have to hold your GLP-1 Agonist for a period of time while you treat your esophageal inflammation. Just as in all medical issues there are many ways to treat side effects of drugs. Your provider will prescribe the medication that she or he is most comfortable with. What next? So if you have reflux and are on a GLP-1 inhibitor, you may be advised to decrease your dose or switch to Tirzepatide medication (Mounjaro, Zepbound). There are many steps you can take before you need prescribed medication. Your doctor may even change your GLP-1 agonist prescription or refer you to a GI doctor, but before this is necessary you should try the lifestyle and dietary changes that I recommend in this Blog first. This side effect of GLP-1 agonists doesn't affect every patient and can be managed as you see above, however the lifestyle changes and dietary changes can only be done by you, so the ball is in your court!

In this month's Digital Health Download, Steve, Halle, and Michael take a deliberately optimistic look at key headlines in healthcare technology. From the impressive impact of AI scribing tools on physician satisfaction to encouraging survival rates among digital health unicorns from the ZIRP-era, the hosts highlights bright spots in an often challenging industry.We cover:

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Struggling to find compounded versions of Semaglutide and Tirzepatide? You're not alone. As these medications become harder to access, many patients are left wondering, "What's next?"In this episode, we sit down with Joe Zucchi, a physician assistant, personal trainer, and clinical supervisor at Transition Medical Weight Loss in Salem, New Hampshire. Joe walks us through the current shortage of compounded medications, what's really going on behind the scenes, and why safe, FDA-approved alternatives are more important than ever. But it's not just about medication. We dive into why obesity isn't just about willpower, discussing how it's a complex issue that goes beyond simple behavior choices. Joe also sheds light on the issue with compounded GLP-1 medications and the risks involved. Plus, he shares practical tips on how to make exercise work for you, whether you're just getting started or looking to refine your routine.Joe's approach to weight management is unique, combining fitness, nutrition, medical treatments, and even an on-site marketplace stocked with healthy, portion-controlled foods. His clinic's well-rounded approach ensures that patients receive the support they need for long-term success, no matter where they are on their weight management journey.Tune in to hear Joe's expert insights and find out how to stay on track with your goals. Don't forget to listen to the full episode!Connect with Mr. Zucchi:Linkedin: Joseph Zucchi, PA-CX: JPZfitness Instagram: transitionweightlossConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Watch Here : https://www.youtube.com/watch?v=2im1dhv11Ck Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

Dr. Jason Bloom is deeply invested in the future of facial aesthetics, teaching around the world and leading clinical research with top aesthetics companies to drive innovation in the field.  As the co-director of the Facial Plastic and Reconstructive Surgery Fellowship at the University of Pennsylvania, he works closely with residents at Temple University and Philadelphia College of Osteopathic Medicine.Dr. Bloom's new, 4,000-square-foot surgery center just outside downtown Philadelphia is a go-to destination for facial aesthetics. With an expert understanding of facial anatomy, he attracts patients from Philly, South Jersey, Delaware, and beyond.Learn more about Philadelphia facial plastic surgeon Dr. Jason BloomFollow Dr. Bloom on Instagram @drjbloomFollow Dr. Bloom's practice on Instagram @bloom.facial.plastics ABOUT MEET THE DOCTOR The purpose of the Meet the Doctor podcast is simple.  We want you to get to know your doctor before meeting them in person because you're making a life changing decision and time is scarce. The more you can learn about who your doctor is before you meet them, the better that first meeting will be. When you head into an important appointment more informed and better educated, you are able to have a richer, more specific conversation about the procedures and treatments you're interested in. There's no substitute for an in-person appointment, but we hope this comes close.Meet The Doctor is a production of The Axis. Made with love in Austin, Texas.Are you a doctor or do you know a doctor who'd like to be on the Meet the Doctor podcast?  Book a free 30 minute recording session at meetthedoctorpodcast.com.

This episode is full of tough love. The reality of your weight loss journey is that nobody is coming to save you. NOBODY! The eff bombs are flying. You've been warned!Irresistible Links

Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

When Karen couldn't shake that last 20 pounds, she considered liposuction. But between the cost and the downtime, it just didn't feel like the right fit for her busy life. That's when she decided to give weight loss medication a try.After surviving breast cancer, Karen struggled to lose weight. At 63, she is actively exploring San Diego, boating, and making the most of life, and she's thrilled that the skinny shot has her feeling more energized, confident, and ready to move.Beyond weight loss, Karen discovered some unexpected perks, like fewer alcohol cravings and an overall boost in her health.She shares all the NSVs (non-scale victories), her best tips for seeing results while feeling great, how she uses ChatGPT to find great recipes, and her experience with the Signature Skinny Shot program at LJCSC.LinksLearn more about the Signature Skinny Shot GLP-1 medical weight loss program at La Jolla Cosmetic Surgery CentreLearn more about the skinny shot and watch our video about getting started on our Signature Skinny Shot YouTube PlaylistLearn from the talented plastic surgeons inside La Jolla Cosmetic, the 20x winner of the Best of San Diego and global winner of the 2020 MyFaceMyBody Best Cosmetic/Plastic Surgery Practice.Join hostess Monique Ramsey as she takes you inside La Jolla Cosmetic Surgery Centre, where dreams become real. Featuring the unique expertise of San Diego's most loved plastic surgeons, this podcast covers the latest trends in aesthetic surgery, including breast augmentation, breast implant removal, tummy tuck, mommy makeover, labiaplasty, facelifts and rhinoplasty.La Jolla Cosmetic is located just off the I-5 San Diego Freeway at 9850 Genesee Ave, Suite 130 in the Ximed building on the Scripps Memorial Hospital campus.To learn more, go to LJCSC.com or follow the team on Instagram @LJCSCWatch the LJCSC Dream Team on YouTube @LaJollaCosmeticThe La Jolla Cosmetic Podcast is a production of The Axis: theaxis.io 

Join JACC Associate Editor Khurram Nasir, MBBS, FACC, and author Rohan Khera, MD, FACC, as they discuss the latest study on tirzepatide presented at ACC.25 and published in JACC. Tirzepatide, a dual GIP/GLP-1 receptor agonist, exerts pleiotropic effects on cardiometabolic health. This study evaluated its efficacy in improving cardiometabolic outcomes in individuals with T2D. An individual participant data meta-analysis was conducted, pooling data from seven Phase 3 RCTs comparing tirzepatide with placebo or standard antihyperglycemic agents. The study outcomes included cardiometabolic components of metabolic syndrome (MetS), elevated BMI, and MetS. Tirzepatide significantly reduced the odds of these abnormalities and effectively resolved MetS, with superior efficacy observed in younger individuals and those not on baseline SGLT2is. These findings support the potential of tirzepatide to improve cardiometabolic health in T2D.

**In this quick episode, Dr. Lisa Faast explains the FDA's recent decision about the tirzepatide shortage and what it means for pharmacies.** **Show Notes:** 1. **FDA Announcement on Turzepatide Shortage** [0:00] 2. **Impact on Compounding and Patient Care** [1:48] 3. **Strategies for Pharmacies to Increase Demand** [3:14] 4. **Final Thoughts and Call to Action** [5:02] Websites Mentioned: https://www.drlisafaast.com/ ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be a Part of the Pharmacy Podcast Network**

In this rare and exclusive interview, the chairman of the Outsourcing Facilities Association sits down with On The Pen to discuss the current landscape of compound tirzepatide. Www.503bs.org

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-425 Overview: In this episode we discuss updates on the treatment and management of obstructive sleep apnea (OSA). This is a common health concern, but it is often underdiagnosed and can have significant health impacts. We review its prevalence and standard treatments, highlighting the recently used medication therapy that has been found to be effective in treating OSA, particularly in individuals with obesity.  Episode resource links: https://www.aafp.org/pubs/afp/issues/2023/0300/uspstf-obstructive-sleep-apnea.html https://emedicine.medscape.com/article/295807-overview Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., ... & Bednarik, J. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M., Chelmow, D., Coker, T. R., ... & US Preventive Services Task Force. (2022). Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement. Jama, 328(19), 1945-1950. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health/ Guest: Mariyan L. Montaque, DNP, FNP-BC  Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________In this episode, we're diving into Ro's innovative approach to weight management with Dr. Steve Silvestro, Associate Director of Clinical Content & Education, and exploring why now is a critical time to discuss telehealth weight loss solutions. With the shortage of Tirzepatide and semaglutide behind us, patients may face more difficulty finding safe, regulated, compounded GLP-1 medications. Many may even consider turning to the black market to obtain research-grade GLP-1s, but it's important to understand the risks involved.Ro offers a regulated and safe alternative: Zepbound vials, which can be prescribed at almost the same cost as compounded tirzepatide, with the added benefit of medical oversight. Dr. Silvestro shares how Ro's personalized care model works to help patients navigate insurance prior authorizations for Zepbound, ensuring a smoother path to treatment.We also hear from two Ro patients, Colleen and Billy, who share their personal community stories and experiences with Ro's platform. They talk about how Ro's holistic approach—addressing everything from diabetes prevention to thyroid conditions like hypothyroidism and Hashimoto's disease—has empowered them to tackle their weight loss journeys and find sustainable health improvements.Ro's approach goes beyond just medication. With a focus on both physical and mental health, they create tailored treatment plans that consider each patient's unique challenges and provide long-term success. If you're looking for insights on safe weight loss solutions, GLP-1 medications, or navigating the complex world of weight management, this episode has you covered.Follow our guests! Billy Facebook: https://www.facebook.com/share/1687JSFHSa/?mibextid=wwXIfrLinkedIn: https://www.linkedin.com/in/billyscharmann?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_appiG: https://www.instagram.com/bill Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-425 Overview: In this episode we discuss updates on the treatment and management of obstructive sleep apnea (OSA). This is a common health concern, but it is often underdiagnosed and can have significant health impacts. We review its prevalence and standard treatments, highlighting the recently used medication therapy that has been found to be effective in treating OSA, particularly in individuals with obesity.  Episode resource links: https://www.aafp.org/pubs/afp/issues/2023/0300/uspstf-obstructive-sleep-apnea.html https://emedicine.medscape.com/article/295807-overview Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., ... & Bednarik, J. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. Mangione, C. M., Barry, M. J., Nicholson, W. K., Cabana, M., Chelmow, D., Coker, T. R., ... & US Preventive Services Task Force. (2022). Screening for obstructive sleep apnea in adults: US Preventive Services Task Force recommendation statement. Jama, 328(19), 1945-1950. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health/ Guest: Mariyan L. Montaque, DNP, FNP-BC  Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

In this episode, host Dr. Seema Khosla explores a transformative development in sleep medicine: the FDA approval of tirzepatide for obstructive sleep apnea (OSA). Joined by an expert panel including Dr. Atul Malhotra, lead investigator of the SURMOUNT-OSA trial, and specialists Dr. Radhika Breaden, Dr. Jeremy McConnell, and Dr. Rafael Sepulveda-Acosta, the discussion examines how sleep clinicians can effectively incorporate this groundbreaking medication into their treatment protocols.  Discover key insights about the SURMOUNT-OSA trial results published in the New England Journal of Medicine, including the mechanisms behind AHI improvement beyond weight reduction alone. Learn practical implementation strategies for private practices, including documentation requirements for insurance approval, necessary baseline labs, and optimal patient follow-up protocols. The experts address crucial questions about Medicare coverage, long-term medication management, the need for retesting at goal weight, and considerations for transitioning patients already using GLP-1 medications like Ozempic or Wegovy.  This episode provides essential guidance for sleep medicine specialists considering expanding their treatment options beyond traditional PAP therapy, including collaborations with obesity medicine clinics and whether obtaining board certification in Obesity Medicine would benefit sleep clinicians. This timely discussion equips practitioners with the knowledge to navigate the intersection of sleep medicine and obesity treatment in managing OSA patients 

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2023:Hydrocortisone in Severe Community-Acquired Pneumonia (0:00 – 5:39).Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes (5:40 – 8:48).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (8:49 – 12:29).Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection (12:30 – 17:49).Early versus Later Anticoagulation for Stroke with Atrial Fibrillation (17:50 – 23:38).And for the Good Stuff:The Beckham docuseries on Netflix (23:39 – 24:15)Upside Drinks (24:16 – 26:04).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

On this episode of the LiverHealthPOD John, Will and Paul discuss the new medications Semaglutide and Tirzepatide including a really interesting study that put these two medications head to head.Find out more in this episode.Don't forget to send us an email at LiverHealthPOD@gmail.com with questions and comment and if you feel up to it. leave some feedback and a rating to help others find us.Thanks for listening.

When to get follow-up labs after starting your diet RxXlear is exonerated!I've been taking tirzepatide and am within range of my desired weight. What is the protocol for coming off this medication?

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Sign The Petition for Avoidable Access to GLP-1s https://glp1collective.org/ ______________________________________________________________________We discuss Wegovy, Ozempic, Mounjaro, Zepbound, Rybelsus, Saxenda, and Victoza and the active ingredients Tirzepatide and Semaglutide. Unlike traditional media, our live sessions offer raw, real-time discussions on obesity treatments, where the community can engage directly in the comments, share their perspectives, and connect with experts and fellow patients. It's a space for honest dialogue, advocacy, and breaking the stigma around obesity, all while staying informed about the latest breakthroughs. Tonight, we are joined by @Downsidezed    / @thedownsized  ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF_____________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Dave discusses the latest in the compound tirzepatide legal battles, cagrisema delivers more big let downs, and some exciting news about VK2735 aka Vikingtide Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

This week please join author Michael Zile and Associate Editor Justin Ezekowitz as they discuss the article "Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20250307.892170

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

Tirzepatide & Weight Maintenance

In this Metabolic Classroom lecture, Dr. Bikman explores GLP-1 receptor agonists (such as Ozempic and Mounjaro) and how to use them more effectively.Ben first explains how GLP-1 is naturally produced in the gut and helps regulate glucagon suppression, slows gastric emptying, and promotes satiety. However, he highlights research showing that individuals with obesity have a blunted GLP-1 response to carbohydrates, which may contribute to overeating. He suggests that GLP-1 drugs could be used more strategically—not just for general weight loss, but specifically to control carbohydrate cravings.While these drugs can promote rapid weight loss, they can also come with serious trade-offs, including mental health risks (depression, anxiety, and suicidal thoughts), lean mass loss (up to 40% of weight lost), diminishing effects over time, and digestive complications such as gastroparesis (stomach paralysis). He critiques the current high-dose, long-term approach to these medications, arguing that most people are not using them strategically and eventually regain lost weight—primarily as fat.Dr. Bikman proposes a better approach to using GLP-1 drugs that focuses on low-dose, short-term usage to help control carbohydrate cravings, rather than suppressing appetite completely.His four-step plan includes: (1) starting at the lowest effective dose, (2) engaging in resistance training to preserve muscle mass, (3) adopting a low-carb, high-protein diet, and (4) cycling off the drug after 3-6 months to assess whether cravings remain under control. He also discusses newer GLP-1/GIP dual agonists like Tirzepatide, which may be even more effective but still require careful usage.In closing, Ben emphasizes that GLP-1 drugs should be a tool, not a crutch.The ultimate goal should be to regain control over eating habits, build long-term dietary discipline, and use the drug only when needed. He encourages those considering these medications to work closely with their healthcare providers and approach them with a long-term metabolic health strategy in mind.Show Notes/References:For complete show notes and references referred to in this episode, we invite you to become a Ben Bikman Insider subscriber. As a subscriber, you'll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben, ad-free Metabolic Classroom Podcast episodes, show notes and references, Ben's Research Reviews Podcast, and a searchable archive that includes all Metabolic Classroom episodes and Research Reviews. Learn more: https://www.benbikman.com Hosted on Acast. See acast.com/privacy for more information.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.     Dapagliflozin plus calorie restriction for remission of type 2 diabetes 2.     Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity 3.     Effectiveness of Empagliflozin vs Dapagliflozin for Kidney Outcomes in Type 2 Diabetes 4.     Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes 5.     Use of SGLT2i Versus DPP-4i as an Add-On Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery)   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Drs. Karl and Spencer discuss with Dr. Grant Tinsley all about the new analysis of how much "lean mass" is lost with tirzepatide, the most powerful medicine available for weight loss.Learn:The difference between fat free mass and lean mass and lean soft tissue and muscle.If GLP-1 medicines cause muscle loss specificallyHow to minimize muscle loss when taking these medicinesOur new study together.Click here for the tirzepatide paperClick here to see Dr. Grant Tinsely's InstagramClick here to join Vineyard

GLP-1 community builder Mike Donnelly-Boylen joins Dave to discuss his health mission and experience losing 100 pounds with Mounjaro! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

In this episode, hosts Brad and Michael are joined by plastic surgeons leading the way in medical weight loss: Dr. Alan Durkin, Dr. Johnny Franco, and Dr. Jonathan Kaplan. They discuss the evolving regulatory landscape surrounding weight loss drugs like tirzepatide and semaglutide, the impact of the FDA removing certain drugs from the shortlist, and key compliance considerations for practices offering these treatments. Tune in for insights on navigating the complexities of medical weight loss from those shaping the industry.  Subscribe to our YouTube channel: https://www.youtube.com/@byrdadatto  Stay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Brain Function Outcomes of Recent and Lifetime Cannabis Use. JAMA Network Open 2025. Discussion by: Guest:Maija Adourian, DOResident– Family Medicine Residency Program Jefferson Health – Abington2. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. Discussion by:Guest:Christopher M. Kramer, MD George A. Beller/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine Chief of the Cardiovascular Division UVA Health3. Screening for Osteoporosis to Prevent FracturesUS Preventive Services Task Force Recommendation Statement. Discussion by:Guest: Anupriya Grover-Wenk, DOFaculty– Family Medicine Residency ProgramJefferson Health – AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Send us a text about this episode. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For Dr. Jason Giles, addiction medicine isn't just a profession—it's a calling shaped by personal experience. In recovery himself, he knows firsthand what it takes to break free from substance dependence. With over 20 years in the field, he combines his deep understanding of addiction with extensive medical expertise to help others reclaim their lives.Before specializing in addiction medicine, Dr. Giles worked in high-intensity trauma, cardiac, and transplant anesthesia. His journey took a turn during a fellowship in pain medicine, where his own recovery, now 25 years strong, led him to addictionology.Today, Dr. Giles cares for patients through treatment centers across California and beyond. He specializes in detox care, helping patients safely transition from substances like alcohol and opiates. His patients value his expertise, empathy, and lived experience as proof that recovery is possible. For Dr. Giles, it's not just about living longer, but living better.To learn more about Los Angeles addictionologist Dr. Jason GilesFollow Dr. Giles on Instagram @drjasongiles ABOUT MEET THE DOCTOR The purpose of the Meet the Doctor podcast is simple.  We want you to get to know your doctor before meeting them in person because you're making a life changing decision and time is scarce. The more you can learn about who your doctor is before you meet them, the better that first meeting will be. When you head into an important appointment more informed and better educated, you are able to have a richer, more specific conversation about the procedures and treatments you're interested in. There's no substitute for an in-person appointment, but we hope this comes close.Meet The Doctor is a production of The Axis. Made with love in Austin, Texas.Are you a doctor or do you know a doctor who'd like to be on the Meet the Doctor podcast?  Book a free 30 minute recording session at meetthedoctorpodcast.com.

OTP legal expert Lee Thomas joins to discuss the latest in the compound Tirzepatide lawsuit. Dr Simin Lee joins Dave to discuss obesity, GLP-1 medications and heart health! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

Welcome back Rounds Table Listeners!We are back today with our Classic Rapid Fire Podcast!This week, Drs. Mike and John Fralick discuss two recent papers - the role of continuous glucose monitoring for diabetes management in hospital and the benefit of tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Two papers, here we go!Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (0:00 – 11:26).DIATEC: A Randomized Controlled Trial (11:26 – 19:56).And for the Good Stuff:Surgeons successfully transplant genetically edited pig kidney into U.S. man (19:56 – 20:55).Diabetes Trial Files (20:55 – 22:25)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

The SUMMIT trial investigated tirzepatide, a dual GIP and GLP-1 receptor agonist, in 731 patients with HFpEF and obesity. This randomized, placebo-controlled study found that tirzepatide reduced heart failure-related events (HR 0.62, P=0.026) and significantly improved quality of life (KCCQ-CSS +19.5 vs. +12.7, P

Send us a textS5 E95 - Tirzepatide for Sleep Apnea & Ryze CocoaIn this episode, Michelle and Daniel explore the newest developments in the use of tirzepatide for treating sleep apnea. They share personal updates and discuss their experiences with new technologies and podcasting remote setups. They delve into the impact of GLP-1 medications on weight loss, mental health, and sleep apnea. Additional topics include the critical balance of lifestyle changes with medication use, the risks associated with GLP-1 medications, and upcoming medical trials for sleep apnea treatments.00:00 Introduction and Podcast Updates00:25 Remote Recording Experiences00:47 Discussion on Podcasting Events03:25 In-Person Events and Giveaways03:41 Rise Cocoa and Nighttime Habits04:06 Tirzepatide and its Implications08:44 Potential Benefits and Risks of GLP-1 Medications16:07 Concerns about Long-term Use27:05 Final Thoughts and Listener AdvisoryWatch on YouTube at https://youtu.be/kmUSmCOdCjgTheme music "Happy Days by FSM Team" courtesy of  https://www.free-stock-music.comLearn More at:Daniel Baughn, Ph.D. at https://www.danielbaughn.com/Michelle Zetoony, M.D. at https://www.dosleep.com/Support the showPlease go to the following page to support the show: https://www.buzzsprout.com/1692604/supportsleeptakeout@gmail.comTheme music "Happy Days by FSM Team" courtesy of https://www.free-stock-music.com Support the showPlease go to the following page to support the show: https://www.buzzsprout.com/1692604/support www.youtube.com/@sleeptakeoutwww.danielbaughn.comwww.dosleep.comsleeptakeout@gmail.com

FIT40 Family Facebook Group: https://www.facebook.com/groups/fit40familyDESCRIPTION:In this comprehensive episode, we dive deep into the world of macronutrients and explore the optimal ratios for a variety of fitness goals, including maintenance, weight loss, muscle gain, and strength training. We'll discuss the science behind macronutrient optimization, provide practical tips for implementing these strategies, and address the unique considerations for individuals on GLP-1 agonists or who have undergone bariatric surgery. Whether you're a seasoned athlete or just starting your fitness journey, this episode is packed with actionable insights to help you unlock your full potential and achieve your desired results.AFFILIATE LINKS:Try Tonal for 30 Days Risk Free: https://tonal.sjv.io/FIT40CONNECT WITH ME ONLINEFacebook: https://www.facebook.com/bryan.fitzsimmonsInstagram: ⁠⁠⁠⁠https://www.instagram.com/coach_fitzz/⁠⁠⁠⁠Tiktok: ⁠⁠⁠⁠⁠https://www.tiktok.com/@coach_fitzz?is_from_webapp=1&sender_device=pcYoutube: https://www.youtube.com/@bryan_fit40 This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit bryanfitzsimmon.substack.com

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/

Ozempic, Wegovy, Mounjaro and all the GLP-1 drugs have taken the weight loss industry by storm! In fact, for the first time in decades, the American Obesity levels have actually gone DOWN in 2024 because of these drugs.But they're still new. And 2 years later, what are my full professional and personal opinions on this wave? Well, check out today's episode to learn.For weight loss tips and coaching that does not include GLP-1, visit www.ThrivingBody.fit

Breaking Compound Tirzepatide News Lilly announces next generation of GLP-1 / GIP med Trump advocates for cheaper "Fat Shot" HIMS faces industry scrutiny Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp

Get My Book On Amazon: https://a.co/d/avbaV48Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/

We're back, after a brief hiatus! Today we talk about duration of therapy for bacteremia, Factor XI inhibition for atrial fibrillation, whether to stop ACEi or ARB before elective surgery, and whether GLP-1 agonists are beneficial in heart failure with preserved ejection fraction. Go to minute 7:30 to skip the banter. 7 vs 14 Days of Antibiotics for Bacteremia (BALANCE)Abelacimab vs Rivaroxaban for Atrial Fibrillation (AZALEA-TIMI-71)Asenduxian vs Apixaban for Atrial Fibrillation (OCEANIC-AF)ACEi or ARB Discontinuation Before Surgery (STOP or NOT)Tirzepatide for HFpEF and Obesity (SUMMIT)Music from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/dopeLicense code: NP8HLP5WKGKXFW2R

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the pros and cons of virtual neurology education, the FDA approval of tirzepatide for obesity-related obstructive sleep apnea, and the promise of AI for glioma assessment.  

Alan's Soaps https://www.alansartisansoaps.comUse coupon code ‘TODD' to save an additional 10% off the bundle price.Bioptimizers https://Bioptimizers.com/ToddEnter promo code TODD to get 10% off any order.Bonefrog https://bonefrogcoffee.com/toddMake Bonefrog Cold Brew at home!  Use code TODD at checkout to receive 10% off your first purchase and 15% on subscriptions.Bulwark Capital Bulwark Capital Management (bulwarkcapitalmgmt.com)Get a second opinion on the health of your retirement portfolio today.  Schedule your free Know Your Risk Portfolio review go to KnowYourRiskRadio.com today.Renue Healthcare https://renue.healthcare/toddYour journey to a better life starts at Renue Healthcare. Visit renue.healthcare/toddMayorkas claimed that Biden and Harris wouldn't let him secure the border. Let's also expose the dark heart of Big Pharma. And, you won't believe what this Episcopal “preacher” claims Luke 8 is actually about.Episode Links:Outgoing DHS Secretary Mayorkas claims Biden and Harris wouldn't let him secure the border. Mayorkas stated multiple times during press conferences that our Southern Border was secure.Kash Patel hands Sen. Amy Klobuchar a heavy dose of competence. War Room is on the move. Minnesota ... Can you see now? Are we ready for a change? It's embarrassing!Trump responds to reporter who questions him on whether DEI contributed to the crash. “You have to go by brain power. You have to go by psychological quality— these are very powerful tests that we put to use and they were terminated by Biden. For an air traffic controller, we want the brightest, the smartest, the sharpest, that's psychologically superior. And that's what we're going to have."President Trump gives a stern reminder to federal workers: “We have informed the federal workforce...that if they're working for the federal government, they must show up to the office...because, as everyone knows, most of the time they're not working, they're not very productive...they'll have to prove that [they aren't working two jobs].”Woke actor Anthony Mackie says Captain America should not represent America:  “He represents a lot of different things & I don't think the term ‘America' should be one of those representations.” Time to boycott the new Captain America movie.Singer Avery starts crying, says she has been diagnosed with a bone-thinning disease from Ozempic, begs her followers not to take the drug. She says she has osteoporosis & osteopenia after taking the drug to lose weight. “Please use me as an example.This is her from a year ago (Jan. 2024). Not saying ozempic can't have nasty side effects, but what happens when you aren't even remotely overweight or diabetic and you take a drug for something you don't have Dr. Robert Lustig discusses weight-loss drugs like Ozempic, Semaglutide, and Tirzepatide: "Yes, there is a 16% weight loss. What is that weight? Turns out it's equal amounts of fat and muscle. Using as much muscle as fat is not a good thing. These two drugs, Semaglutide and also the third one, Tirzepatide, lead to nausea, vomiting, pancreatitis."Episcopal preacher pretends that the story of woman who bled for 12 years in Luke 8 is actually a *pro-LGBTQ* story

Subscriber-only episodeThe Truth About GLP-1 for Weight Loss: Real Stories, Science, and Affordable Access Part 1In this episode, we dive deep into the real story behind obesity and type 2 diabetes, pushing past the outdated ideas of willpower and self-control. We explore how insulin resistance plays a huge role in weight gain and regain and how GLP-1 medications can help tackle these issues. Dr. Lindsay Ogle joins us to break down the science of set weight theory, explaining how our bodies are hardwired to fight weight loss, and why many people with obesity struggle to lose weight with diet and exercise alone. She gives us a better understanding of why GLP-1 medications work differently—targeting the root causes of obesity like insulin resistance—and how they help us break free from the cycle.We also take a hard look at the frustrating realities of getting access to GLP-1 treatments and discuss what other options are out there for managing hunger and preventing weight regain.But it's not just about the science—this episode also digs into the emotional and societal factors that impact obesity. We talk about the importance of seeing obesity for what it is: a complex health condition, not a lack of discipline. Plus, we explore why, in some cases, increasing food intake can actually help people break free from cycles of disordered eating.We also get into the connection between PCOS, binge eating disorder, and Night Eating Disorder, sharing strategies on how to manage them. Ultimately, we're all about taking a holistic approach to obesity—focusing on the whole person and finding the treatment that truly works.Members get early access, and Part 2 will come out next week! Info on our guests: Dr. Lindsay Ogle, MD is a board certified family & obesity medicine physician who is passionate about preventative health. Her goal is to help patients stay healthy so they may live longer and fuller lives. She recently started a telehealth clinic called Missouri Metabolic Health where she helps adults all throughout the state of Missouri treat and prevent metabolic conditions (ex: diabetes, fatty liver disease, metabolic syndrome, overweight and obesity) through lifestyle optimization and utilizations of safe and effective medications. Website: https://missourimetabolichealth.com/Instagram: Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Join CardioNerds Heart Failure Section Chair Dr. Jenna Skowronski, episode lead Dr. Merna Hussein, and expert faculty Dr. Milton Packer as they discuss the SUMMIT trial. The SUMMIT trial randomized 731 patients with HFpEF with LVEF ≥ 50% and obesity with BMI ≥ 30 kg/m2 to receive tirzepatide or placebo for at least 52 weeks. The two co-primary endpoints were a composite of time to cardiovascular death or a worsening heart failure event and quality of life measured by the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS). Treatment with tirzepatide led to a lower risk of the composite of cardiovascular death or worsening heart failure as well as improved quality of life. This episode was planned in collaboration with the American College of Cardiology Section of the Prevention of Cardiovascular Disease with mentorship from Section Chair Dr. Eugenia Gianos. CardioNerds Journal Club PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - The SUMMIT Trial Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., Borlaug, B. A., & SUMMIT Trial Study Group. (2024). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2410027

GLP-1 injections like Semaglutide or Tirzepatide are a game-changer for weight loss...but they aren't magical solutions that will keep the weight off long-term. You have to have a plan in place to work on your emotional weight and change how you think and feel about yourself.  Yes, you want the physical weight loss but what you're actually chasing is a feeling of what you think will automatically happen just because you're at your goal weight.  That feeling won't arrive because you're wearing a size 8. It will happen when you also learn how to think and feel differently about yourself. You need the right tools in your toolkit! Irresistible Links